"Antibodies, Blocking" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that inhibit the reaction between ANTIGEN and other antibodies or sensitized T-LYMPHOCYTES (e.g., antibodies of the IMMUNOGLOBULIN G class that compete with IGE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumors and prevent destruction of tumor cells by CYTOTOXIC T-LYMPHOCYTES have also been called enhancing antibodies. (Rosen et al., Dictionary of Immunology, 1989)
| Descriptor ID |
D019138
|
| MeSH Number(s) |
D12.776.124.486.485.114.143 D12.776.124.790.651.114.143 D12.776.377.715.548.114.143
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Blocking".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Blocking".
This graph shows the total number of publications written about "Antibodies, Blocking" by people in this website by year, and whether "Antibodies, Blocking" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Blocking" by people in Profiles.
-
Sun MM, Chan AM, Law SM, Duarte S, Diaz-Aguilar D, Wadehra M, Gordon LK. Epithelial Membrane Protein-2 (EMP2) Antibody Blockade Reduces Corneal Neovascularization in an In Vivo Model. Invest Ophthalmol Vis Sci. 2019 01 02; 60(1):245-254.
-
Morales SA, Telander DG, Mareninov S, Nagy A, Wadehra M, Braun J, Gordon LK. Anti-EMP2 diabody blocks epithelial membrane protein 2 (EMP2) and FAK mediated collagen gel contraction in ARPE-19 cells. Exp Eye Res. 2012 Sep; 102:10-6.
-
Ji N, Rao N, Guentzel NM, Arulanandam BP, Forsthuber TG. Anaphylaxis and mortality induced by treatment of mice with anti-VLA-4 antibody and pertussis toxin. J Immunol. 2011 Mar 01; 186(5):2750-6.
-
Omosun YO, Adoro S, Anumudu CI, Odaibo A, Holder AA, Nwagwu M, Nwuba RI. Total immunoglobulin G and IgG1 subclass levels specific for the MSP-1(19) of Plasmodium falciparum are different in individuals with either processing-inhibitory, blocking or neutral antibodies. Afr Health Sci. 2010 Jun; 10(2):106-10.
-
Okafor CM, Anumudu CI, Omosun YO, Uthaipibull C, Ayede I, Awobode HO, Odaibo AB, Langhorne J, Holder AA, Nwuba RI, Troye-Blomberg M. Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection. Malar J. 2009 Nov 23; 8:263.
-
Nagata M, Wong T, Clements D, Hui G. Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies. Exp Parasitol. 2007 Apr; 115(4):403-8.
-
Perez-Torres M, Guix M, Gonzalez A, Arteaga CL. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. J Biol Chem. 2006 Dec 29; 281(52):40183-92.
-
Wang SZ, Bao YX, Rosenberger CL, Tesfaigzi Y, Stark JM, Harrod KS. IL-12p40 and IL-18 modulate inflammatory and immune responses to respiratory syncytial virus infection. J Immunol. 2004 Sep 15; 173(6):4040-9.
-
Nwuba RI, Sodeinde O, Anumudu CI, Omosun YO, Odaibo AB, Holder AA, Nwagwu M. The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infect Immun. 2002 Sep; 70(9):5328-31.